[go: up one dir, main page]

KR900001699A - 7-(1-피롤리디닐)-3-퀴놀론-및-나프티리돈카르복실산 유도체, 그의 제조방법 및 그의 제조에 있어서 중간체 생성물로서 치환된 모노- 및 비시클릭 피롤리딘 유도체, 항박테리아제 및 이들을 함유하는 사료 첨가제 - Google Patents

7-(1-피롤리디닐)-3-퀴놀론-및-나프티리돈카르복실산 유도체, 그의 제조방법 및 그의 제조에 있어서 중간체 생성물로서 치환된 모노- 및 비시클릭 피롤리딘 유도체, 항박테리아제 및 이들을 함유하는 사료 첨가제 Download PDF

Info

Publication number
KR900001699A
KR900001699A KR1019890010217A KR890010217A KR900001699A KR 900001699 A KR900001699 A KR 900001699A KR 1019890010217 A KR1019890010217 A KR 1019890010217A KR 890010217 A KR890010217 A KR 890010217A KR 900001699 A KR900001699 A KR 900001699A
Authority
KR
South Korea
Prior art keywords
group
represent
carbon atoms
diazabicyclo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890010217A
Other languages
English (en)
Other versions
KR0156238B1 (ko
Inventor
페테르센 우베
쉔케 토마스
크레브스 안드레아스
그로헤 클라우스
쉬리베르 미카엘
할레르 잉고
게오르그 메츠게르 칼
엔더만 라이너
자일러 한스-요아힘
Original Assignee
클라우스 데너.요아힘 그렘
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25870143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900001699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 클라우스 데너.요아힘 그렘, 바이엘 악티엔게젤샤프트 filed Critical 클라우스 데너.요아힘 그렘
Publication of KR900001699A publication Critical patent/KR900001699A/ko
Priority to KR97053066A priority Critical patent/KR0156375B1/ko
Application granted granted Critical
Publication of KR0156238B1 publication Critical patent/KR0156238B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Fodder In General (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Amplifiers (AREA)

Abstract

내용 없음

Description

7-(1-피롤리디닐)-3-퀴놀론-및 -나프티리돈카르복실산 유도체, 그의 제조방법 및 그의 제조에 있어서 중간체 생성물로서 치환된 모노-및 비시클릭 피롤리딘 유도체, 항박테리아제 및 이들을 함유하는 사료 첨가제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기 일반식(I)의 7-(1-피롤리디닐)-3-퀴놀론-및 -나프티리돈카르복실산 유도체,그의 제약상 이용가능한 수소화물, 산 부가염, 기초가되는 카르복실산의 알칼리금속, 알칼리토금속, 은 및 구아니디늄염,
    식중 X1은 할로겐을 나타내고, X2는 수소원자, 아미노, 1 내지 4개의 탄소원자를 갖는 알킬아미노 알킬기당 1 내지 3개의 탄소원자를 갖는 디알킬아미노 알킬기당 1 내지 3개의 탄소원자를 갖는 디알킬아미노, 히드록실, 1 내지 4개의 탄소원자를 갖는 알콕시, 메르캅토, 1 내지 4개의 탄소원자를 갖는 알킬티오, 아릴티오기 또는 할로겐을 나타내고, R1은 1 내지 4개의 탄소원자를 갖는 알킬, 2 내지 4개의 탄소원자를 갖는 알케닐, 3 내지 6개의 탄소원자를 갖는 시클로알킬, 2-히드록시에틸, 2-플루오로에틸, 메톡시, 아미노, 메틸아미노, 에틸아미노, 디메틸아미노 또는 1 또는 2개의 불소원자에 의해 임의로 치환되는 페닐기를 나타내고, R2는 수소원자, 1 내지 4개의 탄소원자를 갖는 알킬기 또는(5-메틸-2-옥소-1,3-디옥솔-4-일)-메틸기를 나타내고, R3는 하기 구조식의 라디칼을 나타내고,
    [위 구조식에서, R4는 H,C1-C4알킬, 아릴 또는 C1-C4-아실기를 나타내고, R5는 H,C1-C4알킬, OH또는 OCH3기를 나타내고, 또한 R4와R5가 함께 메틸기에 의해 임의로 일치환 또는 이치환되는 C1-C3-알킬렌 다리를 나타낼 수 있으며, R6은 아릴, 헤테로아릴, 벤질, C1-C4-알콕시카르보닐, C1-C4-아실, (5-메틸-2-옥소-1, 3-디옥솔-4-일)-메틸기 뿐만 아니라 H, 임의로 히드록실-치환 C1-C4-알킬, 또는 C3-C6-시클로알킬기를 나타낼 수 있고, R7은 H 또는 C1-C4-알킬기를 나타낼 수 있고, R′는 H,CH3또는 페닐기를 나타낼 수 있고, R″는 H,CH3또는 페닐기를 나타낼 수 있고, R″′는 H 또는 CH3기를 나타낼 수 있고, Y는 O,CH2,CH2CH2또는 CH2-O기를 나타낼 수 있고, CH2-O기가 O 또는 CH2를 거쳐 질소에 연결될 수 있으며, Z는 O 또는 S를 나타낼 수 있음], A는 N 또는 C-R8을 나타낸다. 여기서, R8은 H,할로겐, 메틸,시아노, 니트로, 히드록실 또는 메톡시기를 나타내거나, 또는 R1과 함께 하기 구조식을 갖는 다리를 형성할 수 있다.
  2. 제 1 항에 있어서, X1이 불소 또는 염소를 나타내고, X2가 수소, 아미노, 1 또는 2개의 탄소원자를 갖는 알킬아미노, 디메틸아미노, 히드록실, 메톡시, 메르캅토, 메틸티오, 페닐티오, 불소 또는 염소를 나타내고 R1은 1 내지 3개의 탄소원자를 갖는 알킬, 2 내지 3개의 탄소원자를 갖는 알케닐, 3 내지 5개의 탄소원자를 갖는 시클로알킬, 2-히드록시에틸, 2-플루오로에틸, 메톡시, 아미노, 메틸아미노, 에틸아미노, 디메틸아미노 또는 1 또는 2개의 불소원자에 의해 임의로 치환되는 페닐기를 나타내고, R2는 수소원자, 1 내지 3개의 탄소원자를 갖는 알킬 또는(5-메틸-2-옥소-1,3-디옥솔-4-일)-메틸기를 나타내고, R3는 하기 구조식의 라디칼을 나타내고,
    [위 구조식에서, R4는 H,C1-C3알킬 또는 C1-C2-아실기를 나타내고, R5는 H,C1-C3알킬, OH 또는 OCH3기를 나타내고, 또한 R4와R5가 함께 메틸기에 의해 임의로 일치환 또는 이치환되는 C1-C2-알킬렌 다리를 나타낼 수 있으며, R6는 페닐, 벤질,, C1-C4-알콕시카르보닐, C1-C2-아실, (5-메틸-2-옥소-1, 3-디옥솔-4-일)-메틸 뿐만 아니라 임의로 히드록실-치환된 C1-C3-알킬, 또는 C3-C5-시클로알킬기를 나타낼 수 있고, R7은 H 또는 C1-C2-알킬기를 나타낼 수 있고, R′는 H 또는 CH3기를 나타낼 수 있고, R″는 H 또는 CH3기를 나타낼 수 있고, R″′는 H 또는 CH3기를 나타낼 수 있고, Y는 O,CH2,CH2CH2또는 CH2-O기를 나타낼 수 있고, CH2-O기가 O 또는 CH2를 거쳐 질소에 연결될 수 있으며, Z는 O 또는 S를 나타낼 수 있음], A는 N 또는 C-R8을 나타낸다. 여기서, R8은 H, 불소, 염소, 브롬, 메틸, 니트로, 히드록실 또는 메톡시기를 나타내거나, R1과 함께 하기 구조식을 갖는 다리를 형성할 수 있다.
  3. 제 1 항에 있어서, X1은 불소를 나타내고, X2는 수소, 아미노, 메틸아미노 또는 불소를 나타내고, R1은 1 또는 2개의 탄소원자를 갖는 알킬, 비닐, 시크로프로필, 2-히드록시에틸, 2-플루오로에틸, 메톡시, 메틸아미노, 4-플루오로페닐 또는 2,4-디플루오로페닐기를 나타내고, R2는 수소 또는 1 또는 2개의 탄소원자를 갖는 알킬기를 나타내고, R3는 하기 구조식의 라디칼을 나타내고,
    [위 구조식에서, R4는 H,C1-C2알킬 또는 아세틸기이고, R5는 H 또는C1-C2알킬기를 나타내고, 또한 R4와 R5가 함께 메틸기에 의해 임의로 치환되는 C1-C2-알킬렌 다리를 형성할 수 있으며, R6는 H, CH3,C2H5, HOCH2CH2, 벤질, C1-C4-알콕시카르보닐, C1-C2-아실기를 나타낼수 있고, R7은 H 또는 CH3기를 나타낼 수 있고, R′는 H 또는 CH3기를 나타낼 수 있고, R″는 H 또는 CH3기를 나타낼 수 있고, R″′는 H 또는 CH3기를 나타낼 수 있고, Y는 O,CH2,CH2CH2또는 CH2-O기를 나타낼 수 있고, CH2-O기가 O 또는 CH2를 거쳐 질소에 연결될 수 있으며, Z는 O 또는 S를 나타낼 수 있음], A는 N 또는 C-R8을 나타낸다. 여기서, R8은 H, 불소, 또는 염소를 나타내거나, 또는 R1과 함께 하기 구조식을 갖는 다리를 형성할 수 있다].
    를 나타내는 일반식(I)의 화합물.
  4. 하기 구조식(II)의 화합물을 구조식(III)의 화합물과 필요에 따라 산 도입제의 존재하에 반응시키고, 필요에 따라 R3에 함유된 보호기를 제거하는 것을 특징으로 하는 제1 항의 일반식(I)의 화합물의 제조방법.
    상기식중, R1,R2,X1및 X2는 상기 의미를 갖고, 할로겐, 특히 불소 또는 염소를 나타내고,
    R3-H (III)
    식중 R3는 제 1 항에서 정의한 의미를 갖는다.
  5. 하기 구조식(IV)의 화합물을 구조식(V)의 화합물과 필요에 따라 산도입제 존재하에 반응시키는 것을 특징으로 하는 제 1 항의 일반식(I)의 화합물의 제조방법.
    식중, X1,R1,R2,R3및 A가 상기 정의한 의미를 갖고, X2는 아미노, 1 내지 4개의 탄소원자를 갖는 알킬아미노 알킬기당 1 내지 3개의 탄소원자를 갖는 디알킬아미노, 히드록실, 1 내지 4개의 탄소원자를 갖는 알콕시, 메르캅토, 내지 4개의 탄소원자를 갖는 알킬티오 또는 아릴티오기를 나타냄.
    식중, X1,R1,R2,R3및 A는 상기 정의한 의미를 갖고,
    X2-H
    식중 X2는 상기 정의한 의미를 갖는다.
  6. 하기 일반식(VI)의 화합물을 일반식(VII)의 화합물과 산 도입제 존재하에 반응시키는 것을 특징으로 하는 하기 일반식(Ia)의 화합물의 제조방법.
    식중, X1,X2,R1,R2, 및 A는 상기 정의한 의미를 나타내고, R3는 하기 구조식의 라디칼을 나타내고,
    식중, R4,R5,R6,R1,R″,R″′, Y 및 Z는 상기 정의한 의미를 나타내고,
    식중, X1,X2,R1,R2, 및 A는 상기 정의한 의미를 나타내고, R3a는 하기 구조식의 라디칼을 나타내고,
    식중, R4,R5,R1,R″,R″′, Y 및 Z는 상기 정의한 의미를 갖고,
    R6-Xa(VII)
    식중, R6는 상기 정의한 의미를 나타내고, Xa는 염소, 브롬, 요오드, 히드록실 또는 아식옥시기를 나타낸다.
  7. 사람 또는 동물을 치료하는 방법에 있어서 제 1 항의 일반식(I)의 2-(1-피롤리디닐)-퀴놀린-및-나프티리돈카르복실산 유도체의 용도.
  8. 제 1 항에 의한 일반식(I)화합물을 함유하는 약제.
  9. 약제 제제를 위한 제 1 항의 일반식(I)의 화합물의 용도.
  10. 동물 사료 첨가제로서 제 1 항의 일반식(I)의 화합물의 용도.
  11. 제 1 항에 의한 일반식(I)의 화합물을 함유하는 동물 사료, 또는 동물 사료 첨가제 및 프리믹스.
  12. 하기와 같은 화합물로 구성되는 군의 화합물.
    2-옥사-5,8-디아자비시클로[4.3.0]노난 디히드로클로라이드, 트란스-2-옥사-5,8-디아자비시클로[4.3.0]노난, 5-메탈-2-옥사-5,8-디아지비시클로[4,3,0]노난 디히드클로라이드, 2,8-디아자비시클로[4,3,0] 4-메틸-2,8-디아자비시클로[4.3.0]노난, 2-메틸-2,8-디아자비시클로[4.3.0]노난, 2,7-디아자비시클로[3.3.0]옥탄, 2-메틸-2,7-디아자비시클로[3.3.0]옥탄, 3-옥사-2,7-디아자비시클로[3.3.0]옥탄, 2-메틸-3-옥사-2,7-디아자비시클로[3.30]옥탄,2,5-디메틸-3-옥사-2,7-디아자비시클로[3.3.0]옥탄, 2,8-디메틸-3-옥사-2,7-디아자비시클로[3.3.0]옥탄, 2-메틸-4-옥사-2,8-디아자비시클로[3.3.0]노난, 3-디메틸-4-옥사-2,8-디아자비시클로[3.3.0]옥탄, 2,3-디메틸-2,7-디아자비시클로[3.3.0]옥탄, 에틸-2,7-디아자비시클로[3,3,0]옥탄, -2-카르복실에이트, 2-페닐-2,7-디아자비시클로[3.3.0]옥탄, 4-옥사-2,8-디아자비시클로[4.3.0]노난, 트란스-3-에틸아미노-4-메틸티오-피롤리딘 및 트란스-3-메틸아미노-4-메틸티오-피롤리딘.
  13. 5,6,7,8-테트라플루오로-(2,4-디플루오로페닐)-1,4-히디르로-4-옥소-3-퀴놀린카르복실산, 5,7-디클로로-1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-3-퀴놀린카르복실산 및5,7-디클로로-6-플루오로-1-(2,4-디플루오로페닐)-1,4-디히드로-4-옥소-3-퀴놀린카르복실산.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890010217A 1988-07-15 1989-07-15 7-(1-피롤리디닐)-3-퀴놀론-및 -나프티리돈카르복실산 유도체, 그의 제조 방법, 및 그의 제조를 위한 중간 생성물인 치환된 모노-및 비시클릭 피롤리딘 유도체, 및 이를 함유하는 항균제 및 사료 첨가제 Expired - Lifetime KR0156238B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR97053066A KR0156375B1 (en) 1988-07-15 1997-10-16 Feed additives containing 7-(1-pyrrolidinyl)-3 quinolone and naphthyridone-carboxylic acid derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3824072 1988-07-15
DEP3824072.6 1988-07-15
DE3906365A DE3906365A1 (de) 1988-07-15 1989-03-01 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DEP3906365.8 1989-03-01

Publications (2)

Publication Number Publication Date
KR900001699A true KR900001699A (ko) 1990-02-27
KR0156238B1 KR0156238B1 (ko) 1998-11-16

Family

ID=25870143

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890010217A Expired - Lifetime KR0156238B1 (ko) 1988-07-15 1989-07-15 7-(1-피롤리디닐)-3-퀴놀론-및 -나프티리돈카르복실산 유도체, 그의 제조 방법, 및 그의 제조를 위한 중간 생성물인 치환된 모노-및 비시클릭 피롤리딘 유도체, 및 이를 함유하는 항균제 및 사료 첨가제

Country Status (24)

Country Link
US (4) US4990517A (ko)
EP (2) EP0757990B1 (ko)
JP (2) JP2771853B2 (ko)
KR (1) KR0156238B1 (ko)
CN (3) CN1027165C (ko)
AT (2) ATE135354T1 (ko)
AU (5) AU616277B2 (ko)
CA (1) CA1340114C (ko)
CY (1) CY2111B1 (ko)
DE (4) DE3906365A1 (ko)
DK (1) DK170404B1 (ko)
ES (2) ES2240984T4 (ko)
FI (1) FI94251C (ko)
GR (1) GR3024841T3 (ko)
HK (1) HK1000938A1 (ko)
HU (3) HU213099B (ko)
IE (1) IE81144B1 (ko)
IL (1) IL90940A (ko)
LU (1) LU90645I2 (ko)
NL (1) NL300111I2 (ko)
NO (1) NO168889C (ko)
NZ (1) NZ229914A (ko)
PT (1) PT91165B (ko)
TW (1) TW270119B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7990065B2 (en) * 2006-02-28 2011-08-02 Panasonic Corporation Plasma display panel with improved luminance

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190955A (en) * 1987-01-28 1993-03-02 Bayer Aktiengesellschaft Antibacterial 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
JPH0674261B2 (ja) * 1988-06-21 1994-09-21 塩野義製薬株式会社 キノロンカルボン酸誘導体
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DD285601A5 (de) * 1988-07-15 1990-12-19 Bayer Ag,De Verfahren zur herstellung von 7-(1-pyrrolidinyl)-3-chinolon- und naphthyridoncarbonsaeure-derivaten
US5140033A (en) * 1989-04-03 1992-08-18 Bayer Aktiengesellschaft Antibacterial 5-alkylquinolonecarboxylic acids
US5252734A (en) * 1989-04-03 1993-10-12 Bayer Aktiengesellschaft Antibacterial 5-alkylquinolonecarboxylic acids
DK0393424T3 (da) * 1989-04-17 1996-02-05 Bayer Ag Fremgangsmåde til fremstilling af 2,7-diazabicyclo(3.3.0)octaner
US5241076A (en) * 1989-04-17 1993-08-31 Bayer Aktiengesellschaft 1,4-diazatricyclo [6.3.0.0]undecanes
US5177210A (en) * 1989-04-17 1993-01-05 Bayer Aktiengesellschaft Preparation of 2,7-diazabicyclo(3.3.0)octanes
SE8902076D0 (sv) * 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5214051A (en) * 1989-08-01 1993-05-25 Pfizer Inc. Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed
US5266569A (en) * 1989-08-16 1993-11-30 Pfizer Inc. Azatricyclo carboxylic acids useful as anti-bacterial agents
KR950005301B1 (ko) * 1990-09-04 1995-05-23 주식회사대웅제약 신규한 퀴놀론 카르복실산 유도체
DE4032560A1 (de) * 1990-10-13 1992-04-16 Bayer Ag 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate
US5342846A (en) * 1990-12-05 1994-08-30 Synphar Laboratories, Inc. 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents
ATE194612T1 (de) * 1990-12-05 2000-07-15 Naeja Pharmaceutical Inc 7-substituierte-6-fluor-1,4-dihydro-4-oxo- chinolin-3-carbonsäurederivate als antibakterielle wirkstoffe
ATE196135T1 (de) * 1991-05-28 2000-09-15 Daiichi Seiyaku Co Pyridoncarbonsäurederivate
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DE4121214A1 (de) * 1991-06-27 1993-01-14 Bayer Ag 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate
US5468742A (en) * 1991-07-19 1995-11-21 Bayer Aktiengesellschaft 8-vinyl- and 9-ethinyl-quinolone-carboxylic acids
KR950014567B1 (ko) * 1991-08-01 1995-12-08 주식회사대웅제약 신규한 퀴놀론 카르복실산 유도체
EP0549857A1 (en) * 1991-12-31 1993-07-07 Korea Research Institute Of Chemical Technology Antibacterial quinolone carboxylic acid derivatives
US6004956A (en) * 1992-01-10 1999-12-21 Bayer Aktiengesellschaft Enantiomerically pure 2-oxa-5,8-dizaabicyclo[4.3.0] nonanes and process for their preparation
TW209865B (ko) * 1992-01-10 1993-07-21 Bayer Ag
DE4200415A1 (de) * 1992-01-10 1993-07-15 Bayer Ag Enantiomerenreine 2-oxa-5,8-diazabicyclo(4.3.0)nonane sowie verfahren zu ihrer herstellung
KR960003611B1 (ko) * 1992-07-23 1996-03-20 재단법인 한국화학연구소 신규한 디아자비시클로 알켄 유도체 및 그의 제조방법
KR960003616B1 (ko) * 1992-07-23 1996-03-20 재단법인 한국화학연구소 우수한 항균작용을 갖는 신규한 피리돈 카르복실산 유도체 및 그의 제조방법
DE4232172A1 (de) * 1992-09-25 1994-03-31 Bayer Ag 7-(Aminomethyl-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)chinolon- und Naphthyridoncarbonsäure-Derivate
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
DE4234330A1 (de) * 1992-10-12 1994-04-14 Bayer Ag Chinoloncarbonsäuren
EG20543A (en) * 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
KR940014395A (ko) * 1992-12-09 1994-07-18 강박광 신규한 퀴놀론 유도체 및 그의 제조방법
NO301165B1 (no) * 1992-12-25 1997-09-22 Daiichi Seiyaku Co Bicykliske aminderivater og antibakterielle midler inneholdende disse
KR0148277B1 (ko) * 1993-01-18 1998-11-02 채영복 신규한 플루오르퀴놀론계 유도체 및 그의 제조방법
WO1994025464A1 (en) * 1993-04-24 1994-11-10 Korea Research Institute Of Chemical Technology Novel quinolone carboxylic acid derivatives and process for preparing the same
TW252107B (ko) * 1993-08-27 1995-07-21 Hokuriku Pharmacetical Co Ltd
DE4329600A1 (de) * 1993-09-02 1995-03-09 Bayer Ag Pyrido [1,2,3-d,e] [1,3,4] benzoxadiazinderivate
KR950018003A (ko) * 1993-12-09 1995-07-22 스미스클라인 비참 피엘씨 신규한 퀴놀론 유도체 및 그의 제조 방법
DE4342186A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten
DE4416622A1 (de) * 1994-05-11 1995-11-16 Bayer Ag 8-Amino-10-(azabicycloalkyl)-pyrido[1,2,3-d.e] [1,3,4]benzoxa-diazinderivate
PL181867B1 (pl) * 1994-06-14 2001-09-28 Dainippon Pharmaceutical Co Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL
DE19500792A1 (de) * 1995-01-13 1996-07-18 Bayer Ag Chinolon- und Naphthyridoncarbonsäure-Derivate
AU697025B2 (en) * 1995-01-24 1998-09-24 Hokuriku Seiyaku Co. Ltd Quinoline carboxylic acid
US6024979A (en) * 1995-06-06 2000-02-15 Solvay Animal Health, Inc. Oral veterinary composition containing a fluoroquinolone antibacterial agent possessing superior absorption properties and an extended duration of therapeutic antimicrobial blood levels, and a method of treating a microbial infection in a ruminant
AU715341B2 (en) * 1996-02-23 2000-01-20 Bayer Intellectual Property Gmbh Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8- diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo- 3-quinolin carboxylic acids and their derivatives
US5703244A (en) * 1996-11-21 1997-12-30 Abbott Laboratories Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds
US5874554A (en) * 1996-12-13 1999-02-23 Incyte Pharmaceuticals, Inc. Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
DE19652239A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
KR100219327B1 (ko) * 1997-08-09 1999-09-01 이서봉 퀴놀론 카르복실산 유도체
US6387928B1 (en) * 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
RU2193558C2 (ru) 1997-09-15 2002-11-27 Дзе Проктер Энд Гэмбл Компани Производные хинолона и фармацевтическая композиция на их основе
TR200000752T2 (tr) * 1997-09-25 2000-09-21 Bayer Aktiengesellschaft Etkin terkibin kontrollü salınımı için ilaç formülü.
DE19751948A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
WO1999065918A1 (en) * 1998-06-17 1999-12-23 Daiichi Pharmaceutical Co., Ltd. Enantiomerically pure substituted oxaaza compounds, salts of the same, and processes for the preparation of both
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6197974B1 (en) 1998-10-26 2001-03-06 Abbott Laboratories Enantioselective synthesis of 3-aminopyrrolidines
NZ511554A (en) * 1998-11-10 2003-07-25 Bayer Ag Pharmaceutical preparation of moxifloxacin
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19927412A1 (de) 1999-06-16 2000-12-21 Bayer Ag Verfahren zur Enantiomerenanreicherung von cis-8-Benzyl-7,9-dioxo-2,8-diazabicyclo [4.3.0]nonan
DE19931115A1 (de) 1999-07-06 2001-01-11 Bayer Ag Racemisierung von R, S-Dioxo-Benzylpyrrolopiperidin
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
DE19962470A1 (de) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
RU2297420C2 (ru) * 2000-02-09 2007-04-20 Дайити Фармасьютикал Ко., Лтд. Средство против кислотоустойчивых бактерий, содержащее гетероциклические производные бензоксазина в качестве активного компонента
AU2001234159A1 (en) * 2000-02-25 2001-09-03 Daiichi Pharmaceutical Co., Ltd. Process for producing quinolonecarboxylic acids and intermediates thereof
DE10022369A1 (de) * 2000-05-08 2001-11-15 Bayer Ag Verfahren zur Herstellung von Piperidinen
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
US6579904B1 (en) 2000-09-22 2003-06-17 K.E.R. Associates, Inc. Process for making betaine transition metal complexes for use in animal feed supplements and compositions thereof
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20040073045A1 (en) * 2001-04-06 2004-04-15 Manabu Sasyou Pyrrolidine derivative and process for producing the same
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) * 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2003099815A1 (en) * 2002-05-28 2003-12-04 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
DE10226923A1 (de) * 2002-06-17 2003-12-24 Bayer Ag Verfahren zur Enantiomerenanreicherung von cis-8-Benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonan
US20060252789A1 (en) * 2002-10-31 2006-11-09 Sujay Biswas Amorphous moxifloxacin hydrochloride
SI1594500T1 (sl) * 2003-02-10 2011-02-28 Bayer Schering Pharma Ag Zdravljenje bakterijskih bolezni dihalnih organov z lokalno aplikacijo fluorokinolonov
JP4608922B2 (ja) * 2003-06-27 2011-01-12 東レ・ファインケミカル株式会社 含窒素複素環化合物の製造方法
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
EP1660495B1 (en) 2003-09-04 2007-07-11 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
ITMI20032259A1 (it) * 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
JP4573223B2 (ja) * 2004-01-23 2010-11-04 東レ・ファインケミカル株式会社 光学活性ｔｒａｎｓ−４−アミノ−１−ベンジル−３−ピロリジノールの製造方法
JP2005220081A (ja) * 2004-02-06 2005-08-18 Toray Fine Chemicals Co Ltd ｃｉｓ−４−アミノ−１−ベンジル−３−ピロリジノールの製造方法およびピロリジン誘導体
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
DK2001862T3 (da) * 2006-03-28 2011-08-08 Warner Chilcott Co Llc Malatsalte og polymorfe af (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyklopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolincarboxylsyre
US7456279B2 (en) * 2006-03-28 2008-11-25 The Procter & Gamble Company Coupling process for preparing quinolone intermediates
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
WO2008059223A2 (en) 2006-11-13 2008-05-22 Cipla Limited Process for the synthesis of moxifloxacin hydrochloride
US20080139574A1 (en) 2006-11-30 2008-06-12 Cadila Healthcare Limited Novel quinoline derivatives
US7692015B2 (en) 2007-01-05 2010-04-06 Zheqing Wang Economical process for preparing (S, S)-2, 8-diazabicyclo[4.3.0]nonane and its enantiomer
US7902227B2 (en) * 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
CA2703913A1 (en) * 2007-11-27 2009-06-04 Alcon Research, Ltd. Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
EP2083010A1 (en) 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
KR20100125318A (ko) * 2008-02-15 2010-11-30 알콘 리서치, 리미티드 안과용 플루오로퀴놀론 유도체
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
ATE473977T1 (de) 2008-04-30 2010-07-15 Univ Duisburg Essen Indolä2,3-bü-, indenä1,2-bü- und indenä2,1- büpyridoä2,3-fü quinoxalin-3-carboxylsäuren und ester, verfahren zu ihrer herstellung und ihre verwendung als antivirus- und antitumormittel
EP2145891A1 (en) * 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
CN101429199B (zh) * 2008-09-08 2010-12-15 华东师范大学 外消旋顺式8-苄基-7,9-二氧代-2,8-二氮杂双环[4.3.0]壬烷的制备方法
PL2349220T3 (pl) 2008-10-09 2012-12-31 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny
EA028676B1 (ru) 2008-12-08 2017-12-29 Рациофарм Гмбх Спрессованный моксифлоксацин
WO2010093341A1 (en) * 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
WO2010122774A1 (ja) * 2009-04-20 2010-10-28 株式会社カネカ (１ｓ,６ｓ)または(１ｒ,６ｒ)-シス-２,８-ジアザビシクロ[４.３.０]ノナンおよびその中間体の製造法
NZ596492A (en) 2009-05-15 2013-08-30 Redx Pharma Ltd Redox drug derivatives
CN102675308A (zh) * 2011-03-17 2012-09-19 苏州中科天马肽工程中心有限公司 一种制备8-苄基-2,8-二氮杂二环[4.3.0]壬烷的方法
CN105130967B (zh) * 2011-05-13 2018-04-17 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
CN102964346B (zh) * 2011-09-01 2015-04-22 中国中化股份有限公司 一种制备(S,S)-八氢-6H-吡咯并[3,4-b]吡啶的方法
WO2013056165A1 (en) 2011-10-12 2013-04-18 Yoseph Yaacobi Contact lens cleaning systems
CN102399219A (zh) * 2011-11-18 2012-04-04 太仓市运通化工厂 一种盐酸莫西沙星中间体的制备方法
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
EP2928892B1 (en) 2012-12-04 2018-03-21 Mankind Pharma Ltd. An improved process for the preparation of moxifloxacin hydrochloride
CN105143219A (zh) 2012-12-21 2015-12-09 曼康德研究中心 用于制备作为氮杂双环吡啶衍生物的中间体的(s,s)-6-苄基八氢-1h-吡咯并[3,4-b]吡啶的方法
JP6056036B2 (ja) 2013-01-31 2017-01-11 高砂香料工業株式会社 光学活性２−アリールピペリジニウム塩の製造方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
GR1008168B (el) 2013-03-14 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
US20150045739A1 (en) 2013-08-12 2015-02-12 Novartis Ag Method for treating otic infections after tympanostomy tube placement
GB201322334D0 (en) * 2013-12-17 2014-01-29 Agency Science Tech & Res Maleimide derivatives as modulators of WNT pathway
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления
EP2957561A1 (en) 2014-06-18 2015-12-23 Université Paris 6 Pierre et Marie Curie UPMC Novel fluoroquinolones and use thereof to treat bacterial infections
EP3307741B1 (de) 2015-06-09 2020-10-28 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
US11452732B2 (en) 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
WO2018011017A1 (de) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
CN107602465A (zh) * 2016-07-12 2018-01-19 重庆大学 一种喹诺酮类衍生物及其应用
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
EP3296298A1 (de) * 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
EA038451B1 (ru) * 2016-12-06 2021-08-30 Байер Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновых кислот и их применение
CN113527288A (zh) * 2020-04-16 2021-10-22 沈阳药科大学 喹诺酮羧酸衍生物或二氮杂萘酮羧酸衍生物的制备方法
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE438819B (sv) * 1978-06-19 1985-05-13 Sun Chemical Corp Anordning for applicering av flerfergsbilder pa cylindriska eller stympat koniska foremal
JPS5880989A (ja) * 1981-11-06 1983-05-16 Mitsubishi Electric Corp 静止画テレビジヨン伝送装置の監視制御装置
US4665079A (en) * 1984-02-17 1987-05-12 Warner-Lambert Company Antibacterial agents
US4777175A (en) * 1982-09-09 1988-10-11 Warner-Lambert Company Antibacterial agents
IE55898B1 (en) * 1982-09-09 1991-02-14 Warner Lambert Co Antibacterial agents
JPS60126284A (ja) * 1983-12-09 1985-07-05 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体およびその塩
IT1173374B (it) * 1984-02-24 1987-06-24 Mediolanum Farmaceutici Srl Derivati pirido-benzotiazinici ad elevata attivita' antimicrobica
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
US4698350A (en) * 1984-09-17 1987-10-06 Sterling Drug Inc. 1-ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and antibacterial use thereof
US4657913A (en) * 1985-04-18 1987-04-14 Warner-Lambert Company Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents
US4772706A (en) * 1986-01-13 1988-09-20 Warner-Lambert Company Process for quinoline-3-carboxylic acid antibacterial agents
JPS62215572A (ja) * 1986-03-17 1987-09-22 Kyorin Pharmaceut Co Ltd キノロンカルボン酸誘導体
JPS63198664A (ja) * 1986-03-31 1988-08-17 Sankyo Co Ltd キノロンカルボン酸誘導体
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
US4771055A (en) * 1986-07-28 1988-09-13 Warner-Lambert Company 7-[[3-(aminomethyl)-3-alkyl]-1-pyrrolidinyl]-quinoline-carboxylic acids
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
JPS63179856A (ja) * 1987-01-21 1988-07-23 Kyorin Pharmaceut Co Ltd キノロンカルボン酸誘導体の製造方法並びにその中間体
JPS63297366A (ja) * 1987-05-29 1988-12-05 Sankyo Co Ltd ８−アルコキシキノロンカルボン酸誘導体
JPH0784423B2 (ja) * 1987-06-18 1995-09-13 宇部興産株式会社 ３−アミノ−２−置換ベンゾイルアクリル酸誘導体
JPS643181A (en) * 1987-06-23 1989-01-06 Sankyo Co Ltd Pyridonecarboxylic acid derivative
JPS649992A (en) * 1987-06-30 1989-01-13 Dainippon Pharmaceutical Co 1,8-crosslinked quinolincarboxylic acid derivative, ester thereof and salt thereof
JPH0676400B2 (ja) * 1987-08-25 1994-09-28 大日本製薬株式会社 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩
US5075319A (en) * 1987-09-08 1991-12-24 Sterling Drug Inc. Pyridinyl-quinolone compounds, their preparation and use
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
US4859776A (en) * 1988-03-11 1989-08-22 Abbott Laboratories (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation
JPH0674261B2 (ja) * 1988-06-21 1994-09-21 塩野義製薬株式会社 キノロンカルボン酸誘導体
DD285601A5 (de) * 1988-07-15 1990-12-19 Bayer Ag,De Verfahren zur herstellung von 7-(1-pyrrolidinyl)-3-chinolon- und naphthyridoncarbonsaeure-derivaten
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
AU618823B2 (en) * 1988-07-20 1992-01-09 Sankyo Company Limited 4-oxoquinoline-3-carboxylic acid derivatives, their preparation and their use
JPH0259388A (ja) * 1988-08-25 1990-02-28 Canon Inc 中間調画像記録方法
HU208005B (en) * 1990-02-19 1993-07-28 Kyorin Seiyaku Kk Process for producing optically active 8-methoxy-quinolone-carboxylic acid derivatives and pharmaceutical compositions containing them
DE4301246A1 (de) * 1993-01-19 1994-07-21 Bayer Ag Chinolon- und Naphthyridoncarbonsäurederivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7990065B2 (en) * 2006-02-28 2011-08-02 Panasonic Corporation Plasma display panel with improved luminance

Also Published As

Publication number Publication date
AU650316B2 (en) 1994-06-16
HUT52087A (en) 1990-06-28
AU668287B2 (en) 1996-04-26
GR3024841T3 (en) 1998-01-30
HU9301002D0 (en) 1993-06-28
NL300111I2 (nl) 2003-07-01
EP0757990B1 (de) 2005-03-30
AU671386B2 (en) 1996-08-22
HU208130B (en) 1993-08-30
DE58909894D1 (de) 2005-05-04
IE81144B1 (en) 2000-05-03
ATE135354T1 (de) 1996-03-15
EP0350733B1 (de) 1997-08-20
NO892715D0 (no) 1989-06-29
CN1027165C (zh) 1994-12-28
FI893403A0 (fi) 1989-07-13
NL300111I1 (nl) 2003-04-01
ES2240984T4 (es) 2012-10-08
AU616277B2 (en) 1991-10-24
IE970856A1 (en) 2000-02-23
FI893403A7 (fi) 1990-01-16
HU211472A9 (en) 1995-11-28
KR0156238B1 (ko) 1998-11-16
AU2528692A (en) 1992-11-26
AU7299194A (en) 1994-12-08
US4990517A (en) 1991-02-05
CN1036005C (zh) 1997-10-01
ES2240984T3 (es) 2005-10-16
JPH0269474A (ja) 1990-03-08
US5607942A (en) 1997-03-04
NZ229914A (en) 1992-03-26
AU6055794A (en) 1994-06-09
JP3001848B2 (ja) 2000-01-24
CN1097759A (zh) 1995-01-25
TW270119B (ko) 1996-02-11
EP0350733A2 (de) 1990-01-17
AU3659489A (en) 1990-03-15
PT91165B (pt) 1995-03-01
NO168889C (no) 1992-04-15
LU90645I2 (fr) 2000-12-27
FI94251B (fi) 1995-04-28
FI94251C (fi) 1995-08-10
EP0350733A3 (en) 1990-12-27
DK170404B1 (da) 1995-08-21
DE58909622D1 (de) 1997-09-25
PT91165A (pt) 1990-02-08
US5416096A (en) 1995-05-16
HUT65936A (en) 1994-08-29
NO168889B (no) 1992-01-06
DE19975060I2 (de) 2004-10-14
IE892293L (en) 1990-01-15
NO892715L (no) 1990-01-16
AU658667B2 (en) 1995-04-27
DE3906365A1 (de) 1990-01-18
DK350089D0 (da) 1989-07-14
AU1028392A (en) 1992-02-27
HU213099B (en) 1997-02-28
IL90940A (en) 1994-04-12
JP2771853B2 (ja) 1998-07-02
ATE292127T1 (de) 2005-04-15
CA1340114C (en) 1998-11-03
DK350089A (da) 1990-01-16
EP0757990A1 (de) 1997-02-12
CN1143080A (zh) 1997-02-19
CY2111B1 (en) 2002-04-26
IL90940A0 (en) 1990-02-09
US5059597A (en) 1991-10-22
HK1000938A1 (en) 1998-05-08
CN1039589A (zh) 1990-02-14
JPH10182600A (ja) 1998-07-07
ES2109219T3 (es) 1998-01-16

Similar Documents

Publication Publication Date Title
KR900001699A (ko) 7-(1-피롤리디닐)-3-퀴놀론-및-나프티리돈카르복실산 유도체, 그의 제조방법 및 그의 제조에 있어서 중간체 생성물로서 치환된 모노- 및 비시클릭 피롤리딘 유도체, 항박테리아제 및 이들을 함유하는 사료 첨가제
KR890006540A (ko) I-데속시노지리마이신 및 i- 데속시만노노지리마이신의 n-치환유도체, 이들의 제조방법 및 의약제로서의 용도
DE69030206D1 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung
BR9914379A (pt) Composto, processo para a preparação de um composto, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
KR880005127A (ko) 이미다조 피리딘 유도체 및 이의 제조방법
KR920016424A (ko) 2-치환 퀴놀린, 이들의 제조 방법 및 의약으로서의 이들의 용도
BG100459A (bg) Алкоксиалкилни карбамати от имидазо (1,2-а) пиридини
KR930002320A (ko) 8-비닐-및 8-에티닐-퀴놀론-카르복실산
HUT45538A (en) Process for producing quinoline derivatives and pharmaceutical compositions containing them
AU581324B2 (en) Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
KR920021147A (ko) 피리다진디온 화합물
DE3850603D1 (de) Arylaralkylether, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung.
KR940009184A (ko) 피라졸 축합환 유도체, 이의 제조방법 및 안드로겐 억제제
KR910004633A (ko) 신규한 2-옥소-1옥사-8-아자스피로[4,5]데칸 유도체와 이들을 포함하는 약학적 조성물 및 그 제조방법
KR950702563A (ko) 테트라시클릭 화합물, 이것의 제조방법 및 중간체와, 항암제로서의 이들의 사용방법(tetracyclic compounds process and intermediates for their preparation and their use as antitumour agents)
KR890017252A (ko) 티에노트리아졸로디아제핀 화합물 및 그의 약학적 용도
DE3274860D1 (en) Triazoloquinazolones and their salts, process and intermediates for preparing them, their use as medicines and compositions containing them
KR890012996A (ko) 퀴놀론- 및 나프티리돈 카르복실산 유도체, 그 제조방법, 이 화합물을 함유하는 항균 조성물 및 사료 첨가제
KR900011768A (ko) 신규 치환 피리도 [2,3-d] 피리미던
DE69217613D1 (de) Stickstoff enthaltende bizyklische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
IL75987A (en) Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3161553D1 (en) Thiazolo(3,2-a)pyrimidine derivatives, their preparation and pharmaceutical compositions containing them
RU2008102912A (ru) Сочетание ингибиторов бетта-лактазмы бициклического 6-алкилиденпенема с бетта-лактанным антибиотиком: антибиотик широкого спектра
KR900001701A (ko) 이미다조피라졸 유도체의 진통제 및 항염제로서의 용도
WO2004050081A1 (en) Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890715

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940503

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19890715

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970716

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980213

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980521

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980721

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980721

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010623

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020708

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030702

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20040629

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050621

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060718

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070710

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080701

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20090708

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20100719

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20110630

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20120629

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20120629

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140121

Termination category: Expiration of duration